Researchers Develop mRNA-Engineered Allogeneic MSCs to Deliver T Cell Engagers for Immunotherapy

Researchers have developed a method to engineer allogeneic mesenchymal stem cells (MSCs) using mRNA technology, enabling these cells to deliver T cell engagers and other immunotherapeutic signals in a coordinated manner. The study, published on November 28, 2025, outlines how this approach could potentially enhance the therapeutic capabilities of MSCs in targeting immune-related conditions.

The research demonstrates that by modifying MSCs with mRNA, the cells can be programmed to produce specific proteins that engage T cells and deliver additional immunomodulatory cues. This process allows for precise control over the therapeutic functions of the engineered cells. The study highlights the potential application of this technique in advancing cell-based therapies for diseases involving immune system dysfunction or cancer. Researchers focused on optimizing the delivery mechanisms and ensuring compatibility with allogeneic (donor-derived) MSCs, which are widely used due to their availability and scalability. Further studies will likely explore its clinical implications and safety profiles.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

Related posts:

CDMO Contracts: Drug Patent Watch Highlights Key Elements for Successful Pharmaceutical Development Partnerships Betaine Identified as Molecule That Reduces Inflammation and Aging Pathways Through Exercise 2025 Nobel Prize in Chemistry Awarded for Advancements in Metal-Organic Frameworks Study Finds Slight Increase in Genetic Mutation Rates in Mice Conceived Through Assisted Reproductive Technologies

Author

GOAI